News | Breast Density | May 22, 2019

Paper confirms adding volumetric and visual mammographic density improves risk stratification

VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification

May 22, 2019 — Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast Cancer Risk Evaluation Tool improves breast cancer risk stratification. The research suggests VolparaDensity could be used to help guide personalized medicine through risk-adapted screening.

The study, "A case-control study to add volumetric or clinical mammographic density into the Tyrer-Cuzick breast cancer risk model," was published in the May 11 issue of Journal of Breast Imaging, the official journal of the Society of Breast Imaging.

The paper used visual BI-RADS (Breast Imaging-Reporting and Data System) 4th Edition assessments from breast imaging specialists at the University of Virginia (UVA). It included 474 women who were diagnosed with invasive breast cancer alongside 2,243 controls. The results demonstrated that the addition of volumetric and visual mammographic density measures to classical risk factors improves risk stratification, increasing the number of women accurately identified at high and lower risk of breast cancer.  The Tyrer-Cuzick Tool, one of the most complete and widely used risk models, now accepts VolparaDensity volumetric breast density assessment as a validated breast density input in Version 8.

Based on the study results, researchers concluded that risk could be used to guide precision medicine through risk-adapted screening and prevention strategies. Further, they noted in the discussion that "volumetric breast density assessment has some practical advantages because it is fully automated and has excellent agreement with 3-D breast MRI [magnetic resonance imaging]."

Jack Cuzick, Ph.D., John Snow Professor of Epidemiology, director, Wolfson Institute of Preventive Medicine, and head, Centre for Cancer Prevention, stated, "Including breast density into risk models makes sense. Breast density is a strong risk factor for breast cancer, and it is largely independent of all other known risk factors. Breast density contributes as much information as all other factors combined, nearly doubling the predictive value of the risk model. Screening programs need to take this into consideration in order to develop a personalized breast care plan for each woman."

Eric J. Kraemer, M.D., radiologist at Reno Diagnostic Centers, stated, "Incorporating an objective density measure and the Tyrer-Cuzick risk model has allowed us to better personalize screening for all of our patients. Patients with a lifetime risk of greater than 20 percent are recommended for mammography and MRI screening. The personalized plan for patients with dense breasts but with lower risk includes mammography and automated breast ultrasound (ABUS). For patients that do not have dense breasts and that are at low risk of developing breast cancer, mammography continues to be the gold standard in breast cancer screening. Developing a personalized breast care for each woman depending on her specific risk factors means that we can do a better job at detecting cancer earlier, ensuring that lives are saved."

As one of the clinical applications within VolparaEnterprise, the VolparaDensity clinical application provides radiologists with automated, objective volumetric breast density assessments and a breast density category shown to correlate to BI-RADS 4th and 5th Editions. It is CE-marked and cleared by the U.S. Food and Drug Administration (FDA), Health Canada and the TGA.

For more information: www.volparasolutions.com

Reference

1. Brentnall A.R., Cohn W.F., Knaus W.A., et al. A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model. Journal of Breast Imaging, May 11, 2019. doi.org/10.1093/jbi/wbz006

Related Content

News | Coronavirus (COVID-19)

November 30, 2021 — COVID-19 of mild to moderate severity in pregnant women appears to have no effect on the brain of ...

Time November 30, 2021
arrow
News | Computed Tomography (CT)

November 30, 2021 — A three-year study of more than 1,000 patients found that the risk of delayed intracranial ...

Time November 30, 2021
arrow
News | Coronavirus (COVID-19)

November 29, 2021 — The largest multi-institutional international study to date on brain complications of COVID-19 has ...

Time November 29, 2021
arrow
News | Artificial Intelligence

November 28, 2021 — Lunit, a medical AI provider, is returning to the 107th Radiological Society of North America (RSNA) ...

Time November 28, 2021
arrow
News | Breast Imaging

Lunit, a leading medical AI provider, announced that the U.S. Food and Drug Administration (FDA) 510(k) has cleared its ...

Time November 28, 2021
arrow
News | Breast Imaging

November 24, 2021 — Hologic Inc. will showcase its extensive portfolio of breast and skeletal health products, including ...

Time November 24, 2021
arrow
News | Flat Panel Displays

November 24, 2021 — The rise of digital imaging technology has quickly changed the way in which patient data are used ...

Time November 24, 2021
arrow
News | Coronavirus (COVID-19)

November 24, 2021 — Significant decreases in CT imaging for cancer persisted even after the peak of the COVID-19 ...

Time November 24, 2021
arrow
News | Mammography

November 23, 2021 — Siemens Healthineers has announced the U.S. Food and Drug Administration (FDA) clearance of two new ...

Time November 23, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 23, 2021 — Researchers at Yale University analyzing specialized MRI exams found significant changes in the ...

Time November 23, 2021
arrow
Subscribe Now